Investors Can Lead Class Action Against Nektar Therapeutics Over Alleged Fraud and Protocol Failures

Nektar Therapeutics Investor Alert

On March 26, 2026, it was announced that Nektar Therapeutics (NASDAQ: NKTR) is facing significant legal scrutiny following allegations of securities fraud. Investors who incurred losses stemming from their investments in Nektar are being encouraged to connect with the legal firm, SueWallSt, which is spearheading this class action lawsuit.

A Timeline of Allegations

Between February 26, 2025, and December 15, 2025, the company reportedly misled investors regarding the rigor of its enrollment protocol in the Phase 2b REZOLVE-AA trial. The class action highlights a series of events where Nektar announced completion of its target enrollment, touting strict eligibility criteria. However, the lawsuit claims that these assertions were misleading and did not disclose crucial information regarding the enrollment of ineligible patients.

1. February 26, 2025: Nektar announced completion of the target enrollment for its pivotal REZOLVE-AA trial, citing strict eligibility conditions designed to ensure participant integrity.
2. March 12, 2025: During a conference call, the company's management emphasized unique operational measures aimed at lowering clinical risk while reasserting the stringent eligibility requirements.
3. July 2, 2025: Nektar closed a significant public offering, raising $115 million from the sale of nearly five million shares, reinforcing investor confidence in the narrative being presented.
4. July 29, 2025: The company announced that their candidate drug received FDA Fast Track designation, again detailing the strict enrollment criteria.
5. November 6, 2025: Optimism about the upcoming trial results was voiced by management, reiterating eligibility standards.
6. December 16, 2025: The situation took a turn when it was disclosed that the trial failed to meet its primary endpoint, revealing that four patients involved had major enrollment violations.

The Allegations of Concealment

The lawsuit alleges that while Nektar maintained that the trial was adhering to its rigorous standards, management was aware— or should have been aware— of the violations. For instance, it is claimed that two patients diagnosed with unstable alopecia areata were enrolled less than six months prior to randomization. Additionally, two others allegedly began treatment before completing the required eight-week washout period for prior medications.

These revelations not only question the integrity of the trial data presented to investors but also raise serious concerns regarding the transparency of the company's communications. According to Joseph E. Levi, Esq., a representative from the firm leading the class action, the timely disclosure of material information is critical for maintaining trust in public markets. “This case raises significant questions about the failure to disclose known protocol deviations that investors relied upon for their decision-making,” Levi commented.

Call to Action for Investors

Investors affected by the alleged misconduct have until May 5, 2026, to apply to lead the class action lawsuit. If you purchased Nektar securities within the specified time frame and incurred losses as a result, it is highly advisable to seek legal counsel to explore your options for recovery.

For assistance or inquiries regarding potential claims, investors can reach out to SueWallSt directly at the provided contact information.

As this situation unfolds, the implications for Nektar Therapeutics could be significant, impacting not only investor trust but also the company’s operations and future endeavors.

In conclusion, the allegations against Nektar Therapeutics present a considerable risk for investors, impacting the integrity of the company itself. It remains crucial for stakeholders to remain informed and vigilant as the situation develops and legal proceedings commence.